LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Dual PD-1 and JAK2 Inhibition in Hematological Malignancies
- Status
- WITHDRAWN
- Phase
- PHASE2
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
- Status
- COMPLETED
- Phase
- PHASE2
Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
- Status
- COMPLETED
- Phase
- PHASE3
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
- Status
- TERMINATED
- Phase
- PHASE2
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
- Status
- TERMINATED
- Phase
- PHASE2
Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
- Status
- TERMINATED
- Phase
- PHASE1
Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE2
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
- Status
- COMPLETED
- Phase
- PHASE2
Window of Opportunity Study in Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
CMP-001 for Relapsed and Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1